Future Prospects of Pain Treatment with Botulinum Neurotoxins

  • Bahman Jabbari


Treatment of pain with botulinum neurotoxins is now entering a new era due to the emergence of newly engineered compounds which by targeting the sensory neurons can offer a more effective means of pain control. The preliminary data from cell culture and animal experiments suggest a significant potential for these toxins/toxin chimeras and toxin/antibody compounds in relieving human pain.


Botulinum toxin Botulinum neurotoxin Tetanus toxin A/E chimera Antibody P2X3 receptor Pain 


  1. Burnstock G. Physiopathological roles of p2x receptors in the central nervous system. Curr Med Chem. 2015;22:819–44.Google Scholar
  2. Cernuda-Morollón E, Martínez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine. Headache. 2014;54:987–95.CrossRefPubMedGoogle Scholar
  3. Dai Y, Fukuoka T, Wang H, Yamanaka H, Obata K, Tokunaga A, Noguchi K. Contribution of sensitized P2X receptors in inflamed tissue to the mechanical hypersensitivity revealed by phosphorylated ERK in DRG neurons. Pain. 2004;108:258–66.CrossRefPubMedGoogle Scholar
  4. Ferrari E, Gu C, Niranjan D, Restani L, Rasetti-Escargueil C, Obara I, Geranton SM, Arsenault J, Goetze TA, Harper CB, Nguyen TH, Maywood E, O’Brien J, Schiavo G, Wheeler DW, Meunier FA, Hastings M, Edwardson JM, Sesardic D, Caleo M, Hunt SP, Davletov B. Synthetic self-assembling clostridial chimera for modulation of sensory functions. Bioconjug Chem. 2013;24:1750–9.CrossRefPubMedCentralPubMedGoogle Scholar
  5. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101:366–70.CrossRefPubMedGoogle Scholar
  6. Ma H, Meng J, Wang J, Hearty S, Dolly JO, O’Kennedy R. Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X3 inhibits the release of a pain mediator. Biochem J. 2014;462:247–56.CrossRefPubMedGoogle Scholar
  7. Marinelli S, Luvisetto S, Cobianchi S, Makuch W, Obara I, Mezzaroma E, Caruso. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience. 2010;171:316–28.CrossRefPubMedGoogle Scholar
  8. Marino MJ, Terashima T, Steinauer JJ, Eddinger KA, Yaksh TL, Xu Q. Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior. Pain. 2014;155:674–84.CrossRefPubMedGoogle Scholar
  9. Masuyer G, Chaddock JA, Foster KA, Acharya KR. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol. 2014;54:27–51.CrossRefPubMedGoogle Scholar
  10. Matak I, Riederer P, Lacković Z. Botulinum toxin’s axonal transport from periphery to the spinal cord. Neurochem Int. 2012;61:236–9.CrossRefPubMedGoogle Scholar
  11. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120:2864–74.CrossRefPubMedGoogle Scholar
  12. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, Lawrence GW, Dolly JO. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009;29:4981–92.CrossRefPubMedGoogle Scholar
  13. Nagy I, Friston D, Valente JS, Torres Perez JV, Andreou AP. Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel. Prog Drug Res. 2014;68:39–76.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Bahman Jabbari
    • 1
  1. 1.Botulinum Toxin Treatment ProgramYale School of MedicineNew HavenUSA

Personalised recommendations